Natural history and biology of stage a neuroblastoma: A pediatric oncology group study

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 3, 2000, Pages 197-205

  Alvarado, Carlos S ^a   London, Wendy B ^b   Thomas Look, A ^c   Brodeur, Garrett M ^d   Altmiller, Dale H ^e   Thorner, Paul S ^f   Joshi, Vijay V ^g   Rowe, Susan T ^c   Nash, Michael B ^c   Ide Smith, E ^h   Castleberry, Robert P ⁱ   Cohn, Susan L ^j  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Florida   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g HARTFORD HOSPITAL   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Localized neuroblastoma; MYCN amplification; Prognostic factors; Surgery; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE;

AGE; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DISEASE COURSE; EARLY CANCER; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; ONCOGENE C MYC; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FETAL DISEASES; GENE AMPLIFICATION; GENES, MYC; HEAD AND NECK NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; LIFE TABLES; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; ORGAN SPECIFICITY; PLOIDIES; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; THORACIC NEOPLASMS; TREATMENT OUTCOME; ULTRASONOGRAPHY, PRENATAL;

EID: 0034453338     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200005000-00003     Document Type: Article

References (48)

1. Evans AE, D’Angio GJ, Propert K, et al. Prognostic factors in neuroblastoma. Cancer 1987;59: 1853-9.
2. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31: 2098-103.
3. Jereb B, Bretsky SS, Vogel R, et al. Age and prognosis in neuroblastoma. Review of 112 patients younger than 2 years. Am J Pediatr Hematol Oncol 1984;6: 233-43.
4. Evans AE, Silber JH, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996;14: 2504-10.
5. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1995;13: 884-93.
6. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989;7: 236-44.
7. Kushner BH, Cheung N-KV, LaQuaglia MP, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996;14: 373-81.
8. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol 1988;6: 1271-9.
9. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science 1984;224: 1121-4.
10. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313: 1111-6.
11. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9: 581-91.
12. Bourhis J, DeVathaire F, Wilson GD, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991;51: 33-6.
13. Tsuda T, Obara M, Hirano H, et al. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer 1987;60: 820-6.
14. Shimada H, Chatten J, Newton WA, Jr., et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73: 405-16.
15. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87: 1470-6.
16. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group Study. J Natl Cancer Inst 1997;89: 373-80.
17. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328: 847-54.
18. Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85: 337-84.
19. Kogner P, Barbany G, Dominici C, et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993;53: 2044-50.
20. Borrello MG, Bongarzone I, Pierotti MA, et al. TRK and RET protooncogene expression in human neuroblastoma specimens: High-frequency of TRK expression in non-advanced stages. Int J Cancer 1993;54: 540-5.
21. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55: 4664-9.
22. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334: 225-30.
23. Cohn SL, Look AT, Joshi VV, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 1995;55: 721-6.
24. Rubie H, Hartmann O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 Study. J Clin Oncol 1997;15: 1171-82.
25. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 1992;70: 1685-94.
26. Fabbretti G, Valenti C, Loda M, et al. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol 1993;24: 294-7.
27. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11: 1466-77.
28. Altmiller DH, Rickard R, Parker KM. Measurement of urinary VMA and HVA by capillary gas chromatography and selected-ion monitoring. Clin Chem 1988;6: 1218.
29. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311: 231-5.
30. Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 1993;142: 1339-46.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
32. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35: 1-39.
33. Cox DR. Regression models and life-tables (with discussion). JRSSB 1972;34: 187-220.
34. Efron B. The efficiency of Cox’s likelihood function for censored data. J Am Stat Assoc 1977;72: 557-65.
35. Woods WG, Tuchman M, Bernstein ML, et al. Screening for neuroblastoma in North America. 2-year results from the Quebec Project. Am J Pediatr Hematol Oncol 1992;14: 312-9.
36. Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children’s Hospital. Pediatrics 1993;92: 358-64.
37. Saylors RL, Cohn SL, Morgan ER, et al. Prenatal detection of neuroblastoma by fetal ultrasounography. Am J Pediatr Hematol/Oncol 1994; 16: 356-60.
38. Kushner BH, Cheung N-KV, LaQuaglia MP, et al. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 1996;14: 2174-80.
39. Fong CT, Dracopoli NC, White PS, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989;86: 3753-7.
40. Gehring M, Berthold F, Edler L, et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995;55: 5366-9.
41. Bordow SB, Norris MD, Haber PS, et al. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16: 3286-94.
42. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334: 231-8.
43. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996;14: 25-34.
44. Meddeb M, Danglot G, Chudoba I, et al. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer 1996;17: 156-65.
45. Plantaz D, Mohapatra G, Matthay KK, et al. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997;150: 81-9.
46. Meitar D, Crawford SE, Rademaker AW, et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14: 405-14.
47. Lutz W, Fulda S, Jeremias I, et al. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17: 339-46.
48. Fulda S, Lutz W, Schwab M, et al. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999;18: 1479-86.